2021-11-15T12:06:57-06:00 2020-12-31 ERNST & YOUNG US LLP 99 WOOD AVENUE SOUTH ISELIN NJ 08830 990 2020-01-01 980407553 Foundation for Innovative New Diagnostics % LOUISA CHAUBERT DIR OF FINAN FOUN 0000000000 Chemin des Mines 9 GENEVA SZ 1202 LOUISA CHAUBERT DIRECTOR OF FINANCE 0000000000 2021-11-10 true LOUISA CHAUBERT 999009999 MICHAEL R SALES P01770943 7325164200 3 2020 2022-09-23 18:48:47Z FIND LOUISA CHAUBERT Chemin des Mines 9 GENEVA SZ 1202 98212578 false X www.finddx.org X 2003 SZ The development and implementation of new, low cost diagnostics for infectious diseases for use in low- resource areas. 11 11 142 4 0 0 55842142 97561319 0 0 314122 189810 585117 461449 56741381 98212578 19509593 47562253 0 0 12083872 14824765 0 0 0 24673017 28737822 56266482 91124840 474899 7087738 50956898 107298970 45058424 94312758 5898474 12986212 X FIND is an international non-profit organization that enables the development and delivery of much-needed diagnostic tests for poverty-related diseases. FIND acts as a bridge between experts in technology development, policy and clinical care, reducing barriers to innovation and effective implementation of diagnostic solutions in low-and-middle-income countries. true false 33608830 23793973 0 Covid-19: FIND is co-convening the diagnostics arm of the ACT Accelerator - a global collaboration to accelerate access to COVID-19 tests, treatments, and vaccines for Low Middle Income Countries (LMICs) - with the Global Fund. The aim is to ensure that everyone who needs a test can get one. FIND-specific COVID-19 activities and outputs for 2020 included: i) Comparative evaluation studies of new products that provided supplier-independent, standardized data on 80 SARS-CoV-2 diagnostics. This data is publicly available, enabling end-users to make data-driven decisions; ii) R&D and manufacturing scale-up projects for antigen-based rapid diagnostics tests (Ag RDTs), resulted in volume and price commitments for optimized tests (more robust, nasal, or oral samples), with manufacturing in India and South Africa, and support to a social enterprise model for expanded manufacturing in Senegal and Pakistan; iii) building capacity for COVID-19 diagnosis through training and enabling healthcare workers to obtain the most up-to-date information on COVID-19 testing, with ~25,000 learners enrolled in public and private courses in >190 countries; and iv) a significant project to address bottlenecks in reagent supply for assay development, by supporting antigen production in plant models, where 40% of all proteins are for use in assays for LMICs. 10920188 6753938 0 AMR/OUT: This program has two arms, one with a general remit of pandemic preparedness, and the other specific to the antimicrobial resistance pandemic. Outbreak focus was shifted to Covid-19, so AMR had the higher spend across two workstreams: 1) One Health digital surveillance where two pilot initiatives based on open-source digital technologies were completed in Zambia and Senegal. These systems have provided baseline data and tools for One Health analytics on WHO Glass priority pathogens as well as a broad spectrum of isolates. 2) New diagnostics that will improve gonorrhea management in LMICs to enable stewardship of new antibiotics (under development by GARDP), where the most promising reagents coming out of feasibility assessments were transferred to development of a lateral flow test to meet WHO target product profiles. The largest "outbreaks" project for 2020 aims improve preparedness and response to Lassa fever through R&D and capacity-building activities, the latter with Nigeria as a model that can be replicated in other affected regions. R&D work is still in feasibility phase, a complex project that targets a semi-open platform i.e. where different assay manufacturers can develop reagents that will run off a single device. This model can then be applied beyond Lassa fever. 9239975 5098221 0 TB: The two major focus areas for the TB programmes for 2020 were on i) point of care (POC) tests for TB detection, where the work was mostly R&D; ii) tests for detecting drug-resistant forms of TB (DR-TB), where the work was mostly evidence generation, both through clinical evaluations and usability and acceptability studies and cost-effectiveness analyses. The R&D work is mostly around LAM-based rapid tests, with or without a reader, and around looking at sample collection and concentration technologies and methods that may in future have applicability outside of TB as well. The DR-TB work is by far the largest part of the portfolio with technologies ranging from decentralized fully automated molecular tests for multi- and extensively drug-resistant (TB MDR and XDR- TB) to centralized molecular platforms and next-generation sequencing. The outcome of 2020 work on DR-TB was that two products received regulatory clearance (CE Mark) and evidence from FIND-led studies was provided toward four WHO recommendations. Important amongst these WHO recommendations was one for a line probe assay for pyrazinamide (PZA), which is the only LPA available for PZA - now a key drug for TB - and the only molecular test for PZA reviewed by WHO. The alternative test option (phenotypic DST) is slow, expensive, and requires BSL3. 30987959 11916121 0 84756952 true true false false false false false false false false true false false false false false false true false true true true true false false false false true false true false false false false false false false false false false false false false true true true false false true X 0 0 142 true false true SZ IN SF VM UG false false false false false false false false false false X 11 11 false false false false false false false true true false false false true true true true true true true false X LOUISA CHAUBERT DIR OF FINAN 0000000000 9 chemin des mines geneva SZ 1202 CATHARINA BOEHME CHIEF EXECUTIVE OFFICER 40.0 0.0 X 404938 0 70142 RANGARAJAN SAMPATH CHIEF SCIENTIFIC OFFICER 40.0 0.0 X 322260 0 82621 SERGIO CARMONA CHIEF ACCESS OFFICER 40.0 0.0 X 260711 0 60121 LOUISA CHAUBERT DIRECTOR OF FINANCE 40.0 0.0 X 246180 0 54489 SHARON SAACKS DIRECTOR OF OPERATIONS 40.0 0.0 X 211938 0 54539 MORTEN RUHWALD HEAD OF TUBERCULOSIS 40.0 0.0 X 201179 0 49981 CASSANDRA KELLY DIR. OF EMERGING THREAT 40.0 0.0 X 198078 0 46340 ANITA SURESH HEAD OF SEQUENCING 40.0 0.0 X 198377 0 42201 STEFANO ONGARELLO HEAD OF DATA SRVC. & BIOBANK 40.0 0.0 X 196330 0 40343 SYLVAIN BIELER SENIOR PROJECT MANAGER 40.0 0.0 X 196499 0 32460 SABINE DITTRICH HEAD OF MALARIA & FEVER 40.0 0.0 X 184762 0 39338 BEATRICE MOUTON HEAD OF HUMAN RESOURCES 40.0 0.0 X 187232 0 33989 ELENA IVANOVA TECH. INNOVATION LEAD 40.0 0.0 X 187255 0 27256 SARAH-JANE LOVEDAY HEAD OF COMMUNICATIONS 40.0 0.0 X 174753 0 38205 PAMELA NABETA SENIOR MANAGER QUAL/MED AFFAIR 40.0 0.0 X 181103 0 29458 JOSEPH NDUNG'U HEAD NTD PROGRAM & FIND KENYA 40.0 0.0 X 158722 0 45062 SONJELLE SHILTON HEPATITIS LEAD 40.0 0.0 X 173281 0 26080 HIEDI ALBERT HEAD OF SOUTH AFRICA FIND 40.0 0.0 X 181866 0 1270 JON BASTOW DIR. OF BUSINESS DEV. & RESOUR 40.0 0.0 X 83490 0 3727 ZACHARY BENJAMIN KATZ CHIEF ACCESS OFFICER 40.0 0.0 X 63716 0 13303 MARK KESSEL CHAIRMAN OF THE BOARD 1.0 0.0 X 0 0 0 DANIEL ROBERT CAMUS board member 1.0 0.0 X 0 0 0 ANDREW JOHN JACK board member 1.0 0.0 X 0 0 0 IONA KICKBUSH board member 1.0 0.0 X 0 0 0 CARLOS MOREL MEDICIS board member 1.0 0.0 X 0 0 0 MARCEL TANNER board member 1.0 0.0 X 0 0 0 SHEILA TLOU board member 1.0 0.0 X 0 0 0 MICHAEL WATSON board member 1.0 0.0 X 0 0 0 DAVID HEYMANN board member 1.0 0.0 X 0 0 0 GAO FU board member 1.0 0.0 X 0 0 0 KAMINENI SHOBANA board member 1.0 0.0 X 0 0 0 4012670 0 790925 65 false true false QUANTUMDX LUGANO BUILDING 57 MELBOURNE ST NEWCASTLE 0 UK NE1 2JQ PRODUCT DEV. SUPPORT 14643606 DIAGNOSTIC CONSULTING NETWORK 6354 CORTE DEL ABETO CARLSBAD CA 92011 CONTRACT ASSAY DEV. 5450108 CAPE BIOLOGIX TECHNOLOGIES PTY LD 5 SUNRISE CIRCLE CAPETOWN 0 SF 7405 INCREASE PROD. CAP. 3583427 TRANSNATIONAL TECHNOLOGIES INC 7324 AUBURNWOOD LANE WINDERMERE FL 34786 TEST OPTIMIZATION 2836650 THE BOSTON CONSULTING GROUP LUDWIGTRASSE 21 MUNCHEN 0 GM 80539 STRATEGY CONSULTING 2188000 131 65129908 32431411 97561319 0 189810 189810 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 COMMISSION ON TAX DEDUCTION 900099 20775 20775 OTHER INCOME 900099 440674 440674 461449 98212578 0 651259 5115923 5115923 0 42446330 42446330 0 3057867 2279090 778777 0 9189453 7716386 1473067 1067779 828435 239344 485934 359438 126496 1023732 835834 187898 213648 84624 129024 170057 45670 124387 272978 120665 152313 0 0 0 108318 2165 106153 0 1100923 1052916 48007 1122963 731208 391755 0 996846 125643 871203 747314 663928 83386 0 128095 104009 24086 0 0 20944 20944 51265 937 50328 PROJECT CONTRACTORS 15373041 14422759 950282 EQUIPMENT & SUPPLIES 7772381 7722636 49745 PRINTING & PUBLICATIONS 143044 98356 44688 BANK & SIMILAR CHARGES 516005 516005 91124840 84756952 6367888 0 2054 846 40869754 89676764 0 0 2226115 3199569 0 0 0 0 0 0 0 0 7573565 14136618 74781 47396 46645 27385 0 0 0 0 0 0 0 0 238765 257788 50956898 107298970 7559213 12358346 0 0 37499211 81954412 0 0 0 0 0 0 0 0 0 0 0 0 45058424 94312758 X 5433218 7724169 465256 5262043 5898474 12986212 50956898 107298970 7087738 X false true X true false X 33235693 48242841 59513727 55842142 97561319 294395722 0 0 33235693 48242841 59513727 55842142 97561319 294395722 79359175 215036547 307354 96253 340946 314122 189810 1248485 0 330960 315314 447040 585117 461449 2139880 297784087 0.72212 0.63900 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 74781 47396 27385 27385 true Sub-Saharan Africa 2 3 Program Services SEE PART V 9969762 South Asia 1 86 Program Services SEE PART V 10651718 East Asia and the Pacific 1 3 Program Services SEE PART V 5090270 Europe (Including Iceland and Greenland) 1 79 Program Services SEE PART V 50497238 South America 0 0 Program Services See Part V 1074061 Central America and the Caribbean 0 0 Program Services See Part V 2891 Russia and the Newly Independent States 0 0 Program Services See Part V 671384 Middle East and North Africa 0 0 Program Services See Part V 113883 North America 0 0 Program Services See Part V 1660279 5 171 5 171 79731486 79731486 South Asia Reception of a research materials Sponsored research Analyze HCV RNA COVID-19 Screening and Testing To support TB elimination efforts production of LAM and Mtb Development of diagnotic tests To build a mobile app Study of Xpert MTB/XDR Clinical Development of diagnotic tests Technical Dossier review FIND AFI Study Optimization of the diagnostic network To develop assays TB diagnostics To build a mobile app obtain material for reasearch Development of diagnostic for TB Provide material for publication Consulting services Development of diagnostics Assess HCV self-testing Zika virus diagnostics test SARS-CoV2 immunoassays Storage of specimen samples 2005563 elec fd tran 0 N/A N/A East Asia and the Pacific none 3237936 elec fd tran 0 N/A N/A Europe (Including Iceland and Greenland) none 26903697 elec fd tran 0 N/A N/A North America none 1506939 elec fd tran 0 N/A N/A South America none 921848 elec fd tran 0 N/A N/A Sub-Saharan Africa none 7870347 elec fd tran 0 N/A N/A 113 192 false false false false false false SCHEDULE F, PART I, LINE 2: Contracts are given for research and development of new tools for the diagnosis of infectious diseases. Except for the initial advance payments, payments are conditional upon achievement of milestones or deliverables through the period of the contract as evidenced in contractually specified reports. In addition to the regular reports, program managers monitor progress with regular communications and physical and virtual site visits. Finally, most major grants are subject to annual donor audits which are in addition to the statutory audit. Schedule F, Part I, Line 3, Column E: PROGRAM SERVICE DESCRIPTION In each region, FIND conducted the following program services: Laboratory Strengthening Evaluation Work. Schedule F, Part I, Line 3, Column F all expenditures are reported under the accrual accounting method. Schedule F, Part II, Line 2: Due to the high volume of organizations that were provided assistance from FIND during 2020, it would be difficult for FIND to list each organization and grant amount individually on Schedule F, Part II. Therefore, FIND has listed the total amount of assistance provided for each region in 2020. true Colorado State University US 711 Oval Drive FORT COLLINS CO 805232002 846000545 501 C (3) 31530 0 N/A n/a Diagnostic Consulting Network Inc 6354 CORTE DEL ABERTO CARLSBAD CA 92011 2583053 0 N/A N/A Dimagi Inc 585 MASSACHUSETTS AVE CAMBRIDGE MA 02139 243082 0 N/A N/A Diabetes Technology Society (DTS) 845 Malcom Road Burlingame CA 94010 300012730 501(c)(3) 20250 0 N/A N/A Consolidation of publications Drugs & Diagnostics for Tropical Diseases 4898 Ronson Ct san diego CA 92111 274482027 501 C (3) 279900 0 N/A N/A Exponent 1075 Worcester Street natick MA 01760 70000 0 N/A N/A Johns Hopkins University 733 N Broadway baltimore MD 221051832 520595110 501 C (3) 57899 0 N/A N/A Llamasoft Inc 201 S Division St ANN ARBOR MI 481042259 157400 0 N/A N/A MMU 201 S Division ann arbor MI 48104 16228 0 N/A N/A assessment of molecular ID assay Meso Scale Diagnostics LLC 1601 Research Boulevard rockville MD 20850 6250 0 N/A N/A MRIGlobal 425 Volker Blvd Kansas City MO 641102241 440545878 501(c)(3) 25224 0 N/A N/A Lab testing & system assistance Rutgers The State University of New Jersey 65 Davidson Rd piscataway NJ 088545602 226001086 501 C (3) 102300 0 N/A N/A Sachin Silva 24 Peabody Terrace Apt 1401 Cambridge MA 02138 37720 0 N/A N/A analysis of diagnostics Scanwell Health 800 Wilshire Blvd los angeles CA 90017 240268 0 N/A N/A Serimmune Inc 150 Castilian Drive goleta CA 93117 6000 0 N/A N/A The Broad Institute Inc 415 Main Street cambridge MA 02142 77500 0 N/A N/A The Center for Affordable Health 4938 Hampden Ln 186 bethesda MD 20814 139872 0 N/A N/A The Regents of the University of california 9500 Gilman Drive la jolla CA 920630602 943067788 501 C (3) 283592 0 N/A N/A Treatment Action Group 90 Broad St Suite 2503 new york NY 10004 133624785 501 C (3) 27951 0 N/A N/A University of Washington 4333 Brooklyn Avenue NE Box 359472 seattle WA 98195 916001537 501 C (3) 21706 0 N/A N/A Vitalant dba Vitalant Research Institute 270 Masonic ave SAN FRANSCISCO CA 941184417 860098929 501 C (3) 260658 0 N/A N/A Washington University in St Louis One Brookings Drive ST LOUIS MO 63130 430653611 501 C (3) 47808 0 N/A N/A ZeptoMetrix 872 Main Street BUFFALO NY 14202 39067 0 N/A N/A NONE Biomedical Research Institute 9410 KEY WEST AVENUE ROCKVILLE MD 20850 362229561 501(C)(3) 14556 0 N/A N/A Boston Children's Hospital 300 LONGOOD AVE BOSTON MA 02215 042774441 501(C)(3) 32578 0 N/A N/A Boston University 25 BUICK ST 2ND FL BOSTON MA 02215 042103547 501(C)(3) 12450 0 N/A N/A BroadReach Consulting LLC 2000 M ST NW WASHINGTON DC 20036 65258 0 N/A N/A CHAI -Clinton Health Access Initiation Inc 383 DORCHESTER AVE BOSTON MA 02127 271414646 501(C)(3) 180741 0 N/A N/A 15 14 schedule f, Part I, Line 2 procedures for monitoring use of grant funds Contracts are given for research and development of new tools for the diagnosis of infectious diseases. Except for the initial advance payments, payments are conditional upon achievement of milestones or deliverables through the period of the contract as evidenced in contractually specified reports. In addition to the regular reports, program managers monitor progress with regular communications and site visits. Finally, most major grants are subject to annual donor audits which are in addition to the statutory audit. X true false false false false false false false false CATHARINA BOEHME CHIEF EXECUTIVE OFFICER 352251 0 52687 0 0 0 62505 0 7637 0 475080 0 0 0 RANGARAJAN SAMPATH CHIEF SCIENTIFIC OFFICER 303820 0 18440 0 0 0 64292 0 18329 0 404881 0 0 0 SHARON SAACKS DIRECTOR OF OPERATIONS 203603 0 8335 0 0 0 44058 0 10481 0 266477 0 0 0 LOUISA CHAUBERT DIRECTOR OF FINANCE 228846 0 17334 0 0 0 48125 0 6364 0 300669 0 0 0 CASSANDRA KELLY DIR. OF EMERGING THREAT 184316 0 13762 0 0 0 36612 0 9728 0 244418 0 0 0 SERGIO CARMONA CHIEF ACCESS OFFICER 253946 0 6765 0 0 0 53757 0 6364 0 320832 0 0 0 BEATRICE MOUTON HEAD OF HUMAN RESOURCES 177664 0 9568 0 0 0 33989 0 0 0 221221 0 0 0 JOSEPH NDUNG'U HEAD NTD PROGRAM & FIND KENYA 158722 0 0 0 0 0 34871 0 10191 0 203784 0 0 0 STEFANO ONGARELLO HEAD OF DATA SRVC. & BIOBANK 185803 0 10527 0 0 0 31112 0 9231 0 236673 0 0 0 MORTEN RUHWALD HEAD OF TUBERCULOSIS 196701 0 4478 0 0 0 40476 0 9505 0 251160 0 0 0 SABINE DITTRICH HEAD OF MALARIA & FEVER 177649 0 7113 0 0 0 30391 0 8947 0 224100 0 0 0 SARAH-JANE LOVEDAY HEAD OF COMMUNICATIONS 164879 0 9874 0 0 0 29484 0 8721 0 212958 0 0 0 HIEDI ALBERT HEAD OF SOUTH AFRICA FIND 181866 0 0 0 0 0 1270 0 0 0 183136 0 0 0 ANITA SURESH HEAD OF SEQUENCING 183888 0 14489 0 0 0 32726 0 9475 0 240578 0 0 0 SYLVAIN BIELER SENIOR PROJECT MANAGER 196499 0 0 0 0 0 32460 0 0 0 228959 0 0 0 ELENA IVANOVA TECH. INNOVATION LEAD 173978 0 13277 0 0 0 27256 0 0 0 214511 0 0 0 PAMELA NABETA SENIOR MANAGER QUAL/MED AFFAIR 174580 0 6523 0 0 0 29458 0 0 0 210561 0 0 0 SONJELLE SHILTON HEPATITIS LEAD 164746 0 8535 0 0 0 26080 0 0 0 199361 0 0 0 Schedule J, Part I, Line 4a severance payment Jon Bastow received termination benefits during 2020 in the amount of $18,286. FORM 990, BOX E: THE ORGANIZATION'S TELEPHONE NUMBER IS +41 (22) 710 05 90. FORM 990, PART III, LINE 2: NEW PROGRAM SERVICES In response to the Covid-19 pandemic, FIND has responded with a new program stream, Covid-19 and pandemic preparedness. The details of the program are described in Part III Line 4. FORM 990, PART III, LINE 4D: other program SERVICES program services for Access, Fever & Malaria, HCV & HIV, and Neglected Tropical Diseases. A summary of each program is given below. PROGRAM - Access: Expenses - $15,437,143 including grants $3,183,085 Program scope is broad with multiple focus areas that will ultimately enable access to testing. For India, 2020 included COVD-19 response work (testing, sequencing, reagent development). With traditional TB programs at risk, we worked to strengthen bi-directional screening. Despite COVID, TB lab work continued - Karnataka became India's first state where all three Intermediate Reference Laboratories achieved ISO accreditation. EQA methods were established in >1,100 sites, and quality TB care services extended to private sector patients (~190,000 patients notified >82% successful treatment outcomes reported in a 3-month period). We also continued to work on micro-elimination of HCV in prisons and had two community-based delivery model projects running in India. These projects (another is in Senegal) target TB and diabetes as a leading co-morbidity factor for TB patients, cater to rural communities and leverage existing networks, such as women-led community groups. Diagnostic network optimization (DNO) was carried out in Central African Republic, the Gambia, India, and Rwanda. DNO analysis that matches testing demand with testing capacity increases access, improves efficiency, and develops routing for specimen referral networks. This project was adapted to respond to COVID-19 testing demands. PROGRAM - Fever & Malaria: Expenses - $4,052,356 including grants of $2,098,277 The work for malaria targets tools to meet one of the few remaining diagnostic gaps in malaria, specifically robust tools to use in P. vivax malaria elimination. For fever, our primary focus is tools for differential diagnosis of patients who present with fever at the primary healthcare level where studies have confirmed ~90% of patients with a negative malaria test received antibiotics, fueling anti-microbial resistance. PROGRAM - HCV and HIV: Expenses - $6,442,490 including grants of $3,679,160 The work was for HCV only, and bulk of 2020 work was on 1) sampling methods that eliminate cold chain needs, critical for increasing access to testing at lower levels of the healthcare system; it also allows for integration into existing HIV DBS systems; and 2) evaluation of self-testing that includes using portable molecular diagnostics shown that this approach can help overcome apathy towards testing and mitigate barriers to clinic based testing. PROGRAM - NTDs: Expenses - $5,055,970 including grants of $2,955,599 FIND works on five different NTDs: Chagas disease, Buruli ulcer, sleeping sickness, visceral leishmaniasis and schistosomiasis. Work in each of these disease areas is shaped to address primary gaps in elimination strategies, for example for HAT, in 2020 we started shaping our ongoing R&D and large-scale country projects to be in line with changing elimination strategies and supply challenges (which is a common problem for tests for NTDs). Form 990, Part V, Line 2a and Part VII, Section A Individuals employed by the FIND are not U.S. Residents or U.S. employees. Information pertaining to the number of employees and employee compensation is provided using the best information available from equivalent W-2 and W-3 Forms for the various countries in which the FIND employs individuals. FORM 990, PART VI, LINE 11B: FORM 990 REVIEW PROCESS THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM AND REVIEWED BY THE DIRECTOR OF FINANCE. ONCE APPROVED BY THE DIRECTOR OF FINANCE, THE FORM 990 IS ALSO REVIEWED BY THE CEO. ADDITIONALLY, IN 2019 FIND PARTICIPATED IN A BENCHMARKING EXERCISE WITH PEER ORGANIZATION TO ENSURE CONSISTENCY OF TREATMENT OF VARIOUS ITEMS ON FORM 990. FORM 990, PART VI, LINE 12C: FIND's conflict of interest policy requires directors, officers and key employees, all other staff members, board members consultants and partners to disclose actual or potential conflicts of interest when they arise. The person or company is also required to recuse themselves from any decision making. FORM 990, PART VI, LINES 15A & 15B: COMPENSATION REVIEW AND APPROVAL PROCESS A review by an independent consultant of the CEO's remuneration package was done by the Board and forms the basis of written employment contract. Remuneration terms for officers and key employees are based on market rates for similar positions in specific locations. This benchmarking is done against an independent report which presents data collected for similar organizations and this exercise is done every 3 years. Salaries for all staff are available to the Board and Compensation Committee. However, the salaries of the C-suite and other key staff are approved by the Compensation Committee. FORM 990, PART VI, LINES 19: AVAILABILITY OF GOVERNING DOCUMENTS TO THE PUBLIC FIND's governing documents (Statutes and By-Laws) Conflict of Interest policy and Financial Statements are available for inspection at FIND's offices in Geneva upon request. FORM 990, PART VI, LINE 20: Books in care of phone number The telephone number of the person who possesses the books and records is: +41 (22) 710 05 90. FIND INDIA FLAT NO 8 9TH FL 17 BARAKHAMBA RD NEW DELHI IN 110001 PROGRAM SVCS IN N/A N/A FIND SWISS true FIND DX NPC 89 ROODEBLOEM ROAD WOODSTOCK CAPE TOWN SF PROGRAM SVCS SF N/A N/A FIND SWISS true FIND DX KENYA OFF MBAGATHI RD PO BOX 54840 NAIROBI KE 00200 PROGRAM SVCS KE N/A N/A FIND SWISS true false false false false false false false false false false false false false false false false false true false find india r 1419044 fmv find dx npc r 329400 fmv